Amicus Therapeutics, Inc.
FOLD · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $169,061 | $154,688 | $125,249 | $149,706 |
| % Growth | 9.3% | 23.5% | -16.3% | – |
| Cost of Goods Sold | $21,341 | $15,217 | $11,698 | $14,836 |
| Gross Profit | $147,720 | $139,471 | $113,551 | $134,870 |
| % Margin | 87.4% | 90.2% | 90.7% | 90.1% |
| R&D Expenses | $23,415 | $60,848 | $27,839 | $30,190 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $90,036 | $84,543 | $91,827 | $86,668 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $3,554 | $1,837 | $2,041 |
| Operating Expenses | $113,451 | $148,945 | $121,503 | $118,899 |
| Operating Income | $34,269 | -$9,474 | -$7,952 | $15,971 |
| % Margin | 20.3% | -6.1% | -6.3% | 10.7% |
| Other Income/Exp. Net | $5 | -$9,707 | -$10,093 | -$8,037 |
| Pre-Tax Income | $34,274 | -$19,181 | -$18,045 | $7,934 |
| Tax Expense | $16,968 | $5,239 | $3,641 | -$6,805 |
| Net Income | $17,306 | -$24,420 | -$21,686 | $14,739 |
| % Margin | 10.2% | -15.8% | -17.3% | 9.8% |
| EPS | 0.056 | -0.08 | -0.07 | 0.049 |
| % Growth | 170.1% | -14.3% | -242% | – |
| EPS Diluted | 0.056 | -0.08 | -0.07 | 0.049 |
| Weighted Avg Shares Out | 308,468 | 308,254 | 307,689 | 299,042 |
| Weighted Avg Shares Out Dil | 310,433 | 308,254 | 307,689 | 299,042 |
| Supplemental Information | – | – | – | – |
| Interest Income | $829 | $843 | $812 | $1,416 |
| Interest Expense | $11,711 | $11,565 | $11,455 | $11,958 |
| Depreciation & Amortization | $1,874 | $1,852 | $1,837 | $2,041 |
| EBITDA | $47,859 | -$5,764 | -$4,753 | $21,933 |
| % Margin | 28.3% | -3.7% | -3.8% | 14.7% |